Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.
The region’s largest health insurer said it will only cover the drug for its FDA-approved uses ... diabetes drugs for the purposes of weightloss. Independence Blue Cross said starting Jan ...